{"id":"amiodarone-injectable-solution","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Hypotension"},{"rate":"5-10","effect":"Bradycardia"},{"rate":"5-10","effect":"Phlebitis at injection site"},{"rate":"5-10","effect":"Nausea"},{"rate":"1-5","effect":"Pulmonary toxicity (chronic use)"},{"rate":"5-10","effect":"Thyroid dysfunction (chronic use)"},{"rate":"1-3","effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL1083993","moleculeType":"Small molecule","molecularWeight":"681.78"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amiodarone works primarily by blocking cardiac potassium channels, which delays repolarization and extends the action potential duration. It also has properties of Classes I, II, and IV antiarrhythmics, providing additional effects on sodium and calcium channels as well as beta-adrenergic blockade. This multi-channel activity makes it effective for suppressing various types of cardiac arrhythmias.","oneSentence":"Amiodarone is a Class III antiarrhythmic agent that blocks potassium channels and prolongs the action potential duration and refractory period to restore normal heart rhythm.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:01:13.413Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ventricular fibrillation"},{"name":"Ventricular tachycardia"},{"name":"Atrial fibrillation with rapid ventricular response"},{"name":"Supraventricular tachycardia"}]},"trialDetails":[{"nctId":"NCT05549752","phase":"PHASE3","title":"Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia","status":"RECRUITING","sponsor":"Hippocration General Hospital","startDate":"2023-03-24","conditions":"Atrial Fibrillation Paroxysmal, Coronary Artery Disease Without Residual Ischemia","enrollment":80},{"nctId":"NCT05445297","phase":"PHASE4","title":"Refralon Versus Amiodarone for Cardioversion of Paroxysmal Fibrillation and Atrial Flutter","status":"COMPLETED","sponsor":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","startDate":"2022-01-26","conditions":"Atrial Fibrillation Paroxysmal","enrollment":60},{"nctId":"NCT03855826","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.","status":"UNKNOWN","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2019-01-15","conditions":"Ventricular Tachycardia, Ventricular Fibrillation","enrollment":756}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Amiodarone Injectable Solution","genericName":"Amiodarone Injectable Solution","companyName":"Hippocration General Hospital","companyId":"hippocration-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amiodarone is a Class III antiarrhythmic agent that blocks potassium channels and prolongs the action potential duration and refractory period to restore normal heart rhythm. Used for Ventricular fibrillation, Ventricular tachycardia, Atrial fibrillation with rapid ventricular response.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}